Journal of mucopolysaccharidosis and rare diseases

Association for Research of MPS and Rare Diseases (뮤코다당증연구학회)
권호 표지
DOI QR코드

DOI QR Code

Improving Adherence to Growth Hormone (GH) Therapy via EasypodTM May Help Maximize the Treatment Outcome

  • Received : 2015.06.21
  • Accepted : 2015.06.28
  • Published : 2015.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

In Growth Hormone (GH) therapy, suboptimal adherence is a common problem, reaching up to 82%, and there is a need for interventions to improve adherence and to maximize patients' growth potential eventually. Current studies have demonstrated the association between the rate of non-adherence and reduced height velocity. In order to maximize patients' potential to grow, an auto-injecting/recording device, such as $easypod^{TM}$, may help improve adherence and optimize the treatment effects of GH therapy. The use of $easypod^{TM}$ has contributed to high adherence rates: 87.5% and 93% in Bozzola et al.'s study and the $Easypod^{TM}$ Connect Observational study (ECOS), respectively. Improvement of adherence by $easypod^{TM}$ may lead to higher growth rates of patients receiving GH therapy. Additionally, patients' positive acceptability of $easypod^{TM}$ suggests $easypod^{TM}$ is a preferred device by patients for better adherence.

Keywords

References

  1. World Health Organisation. Adherence to long-term therapies - Evidence for action. 2003.
  2. Fisher BG, Acerini CL. Understanding the Growth Hormone Therapy Adherence Paradigm: A Systematic Review. Horm Res Paediatr 2013;79:189-96. https://doi.org/10.1159/000350251
  3. Cutfield WS, et al. Non-compliance with Growth Hormone Treatment in Children Is Common and Impairs Linear Growth. PLos ONE. 2011;6:e16223. https://doi.org/10.1371/journal.pone.0016223
  4. $Saizen^{(R)}$ Summary of Product Characteristic.
  5. Matsui DM. Drug compliance in pediatrics: clinical and research issues. Pediatr Clin North Am 1997;44:1-14. https://doi.org/10.1016/S0031-3955(05)70459-4
  6. Bozzola M, et al. Treatment adherence with the $easypod^{TM}$ growth hormone electronic auto-injector and patient acceptance: survey results from 824 children and their parents. BMC Endocrine Disorders 2011;11:4. https://doi.org/10.1186/1472-6823-11-4
  7. Dahlgren J, et al. Patient acceptance of a novel electronic auto-injector device to administer recombinant human growth hormone: results from an open-label, user survey of everyday use. Curr Med Res Opin. 2007;23:1649-55. https://doi.org/10.1185/030079907X210589
  8. Aydin B, et al. Adherence to Growth Hormone Therapy: Results of a Multicenter Study. Endocrine Practice. 2014;20:46-51. https://doi.org/10.4158/EP13194.OR
  9. Kapoor RR, et al. Monitoring of concordance in growth hormone therapy. Arch Dis Child.2008;93:147-8. https://doi.org/10.1136/adc.2006.114249
  10. Davis P, et al. The $Easypod^{TM}$ Connect Observational Study (ECOS): Results from the 2014 Interim Analysis. Endocrine Society's 97th Annual Meeting, March 2015. THR-160 (Meeting Abstract).